Charles Roman, DO
Internal Medicine · Columbus, GANPI 1487636577
Payments from drug & device makers
Across 168 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$516
- Lilly USA, LLC$421
- Bayer$232
- AbbVie$219
- Astellas Pharma US Inc$216
- Boehringer Ingelheim$183
- plus $978 from 21 others
What the payments were for
- Food & beverage$2,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $516 |
| Lilly USA, LLC | 28 | $421 |
| Bayer | 12 | $232 |
| AbbVie | 15 | $219 |
| Astellas Pharma US Inc | 10 | $216 |
| Boehringer Ingelheim | 11 | $183 |
| GSK | 9 | $162 |
| Pfizer | 8 | $128 |
| Abbott | 5 | $109 |
| Johnson & Johnson | 7 | $89 |
| Dexcom, Inc. | 4 | $85 |
| Amgen(2 entities) | 4 | $65 |
| Inspire Medical Systems, Inc. | 1 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Merck | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Exact Sciences | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,765 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $337,217 |
| JardianceEmpagliflozin | 192 | $255,401 |
| MounjaroTirzepatide | 128 | $229,979 |
| EliquisApixaban | 170 | $194,031 |
| JanuviaSitagliptin Phosphate | 108 | $128,700 |
| BetaseronInterferon Beta-1b | 11 | $96,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $95,204 |
| TrulicityDulaglutide | 42 | $91,740 |
| RybelsusSemaglutide | 44 | $80,201 |
| MyrbetriqMirabegron | 64 | $61,461 |
| FarxigaDapagliflozin Propanediol | 42 | $58,514 |
| LinzessLinaclotide | 35 | $44,336 |
| TradjentaLinagliptin | 34 | $42,239 |
| PrezcobixDarunavir/Cobicistat | 12 | $29,604 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $25,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $516 | $417,418287 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $183 | $330,534287 claims |
| Lilly USA, LLCMounjaro, Trulicity | $421 | $321,719170 claims |
| PfizerEliquis | $128 | $194,031170 claims |
| MerckJanuvia, Isentress | $34 | $153,107120 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $162 | $118,338184 claims |
| BayerBetaseron | $232 | $96,95511 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $16 | $90,273117 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $61,46164 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $89 | $50,61727 claims |
| AbbVieLinzess | $219 | $44,33635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Columbus
- Anthony OlofintuyiColumbus$1.2M
- Joshua SamrajColumbus$241K
- Ricardo AlvarezColumbus$199K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.